DEALS
Zhong Lun Advised on Anpac’s IPO on NASDAQ
Zhong Lun Advised on Anpac’s IPO on NASDAQ
On January 31, 2020, Anpac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) completed its initial public offering of depositary shares, which have been listed on the Nasdaq Global Market.
Zhonglun Law Firm acted as Anpac’s PRC legal counsel in the offering. The legal team from Zhonglun was led by partners Anthony Zhao, William Jia, Xiong Chuan. Other project team members include lawyers Roy Zheng, Ye Yunting, etc. Xiao Ling, partner of Zhonglun's New York Office, provided strong support.
Anpac is a biotechnology company dedicated to early cancer screening. Anpac has certified clinical laboratories in China and the United States that perform a range of cancer screenings and tests, including CDA, biochemical tests, immunological and genetic tests.
Professionals
-
-
Anthony ZHAO
Equity Partner
ShanghaiPractices： Hong Kong & Overseas Capital Markets,Private Equity & Investment Funds,Cross-border Investment/M&AIndustries： Telecommunications & Internet,Information & Intelligence Technology,Healthcare,Pharmaceuticals & Life Sciences,Education & Training,Media-Sports & Entertainment,Banking & Financial Services,Financial Innovation & Fintech -
Anthony ZHAO
Equity Partner
Shanghai
-
-
-
William JIA
Equity Partner
ShanghaiPractices： Hong Kong & Overseas Capital Markets,Chinese Mainland Capital Markets,Cross-border Investment/M&AIndustries： Financial Innovation & Fintech,Telecommunications & Internet,Information & Intelligence Technology,Pharmaceuticals & Life Sciences,Media-Sports & Entertainment -
William JIA
Equity Partner
Shanghai
-
